RU2449794C2 - Применение 10-[(3r)-1-азабицикло[2.2.2]окт-3-илметил]-10н-фенотиазина для изготовления лекарства, селективно ингибирующего мускариновые рецепторы м1, м2 и м3 - Google Patents
Применение 10-[(3r)-1-азабицикло[2.2.2]окт-3-илметил]-10н-фенотиазина для изготовления лекарства, селективно ингибирующего мускариновые рецепторы м1, м2 и м3 Download PDFInfo
- Publication number
- RU2449794C2 RU2449794C2 RU2009128326/15A RU2009128326A RU2449794C2 RU 2449794 C2 RU2449794 C2 RU 2449794C2 RU 2009128326/15 A RU2009128326/15 A RU 2009128326/15A RU 2009128326 A RU2009128326 A RU 2009128326A RU 2449794 C2 RU2449794 C2 RU 2449794C2
- Authority
- RU
- Russia
- Prior art keywords
- azabicyclo
- oct
- phenothiazine
- ylmethyl
- urinary incontinence
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 229940079593 drug Drugs 0.000 title claims abstract description 15
- 230000002401 inhibitory effect Effects 0.000 title description 6
- 206010046543 Urinary incontinence Diseases 0.000 claims abstract description 43
- HOKDBMAJZXIPGC-MRXNPFEDSA-N 10-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]methyl]phenothiazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1C[C@@H]1C(CC2)CCN2C1 HOKDBMAJZXIPGC-MRXNPFEDSA-N 0.000 claims abstract description 25
- 230000005764 inhibitory process Effects 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 230000001580 bacterial effect Effects 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 2
- 208000013403 hyperactivity Diseases 0.000 claims abstract 2
- 230000008602 contraction Effects 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 6
- 210000005070 sphincter Anatomy 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 3
- 230000003872 anastomosis Effects 0.000 claims description 3
- 230000027939 micturition Effects 0.000 claims description 3
- 210000003708 urethra Anatomy 0.000 claims description 3
- 208000008967 Enuresis Diseases 0.000 claims description 2
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims description 2
- 206010029279 Neurogenic bladder Diseases 0.000 claims description 2
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 239000006213 vaginal ring Substances 0.000 claims description 2
- 239000002496 intravaginal dosage form Substances 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 229950000688 phenothiazine Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 229940044953 vaginal ring Drugs 0.000 claims 1
- HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 abstract description 45
- 230000000694 effects Effects 0.000 abstract description 23
- 230000001078 anti-cholinergic effect Effects 0.000 abstract description 21
- 238000001727 in vivo Methods 0.000 abstract description 13
- 230000007423 decrease Effects 0.000 abstract description 6
- 230000006870 function Effects 0.000 abstract description 3
- 210000004400 mucous membrane Anatomy 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000036387 respiratory rate Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 description 44
- 108020003175 receptors Proteins 0.000 description 44
- 150000001875 compounds Chemical class 0.000 description 21
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 20
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 20
- 210000003932 urinary bladder Anatomy 0.000 description 14
- 230000028327 secretion Effects 0.000 description 13
- 210000003296 saliva Anatomy 0.000 description 12
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 10
- 229960004373 acetylcholine Drugs 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 7
- 206010039424 Salivary hypersecretion Diseases 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 239000000812 cholinergic antagonist Substances 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 229930003347 Atropine Natural products 0.000 description 5
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 5
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 5
- 229960000396 atropine Drugs 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 206010013781 dry mouth Diseases 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- 230000003551 muscarinic effect Effects 0.000 description 5
- 229960005434 oxybutynin Drugs 0.000 description 5
- HOKDBMAJZXIPGC-INIZCTEOSA-N 10-[[(3s)-1-azabicyclo[2.2.2]octan-3-yl]methyl]phenothiazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1C[C@H]1C(CC2)CCN2C1 HOKDBMAJZXIPGC-INIZCTEOSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 208000008630 Sialorrhea Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000001022 anti-muscarinic effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000036724 intravesical pressure Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 4
- 229960004045 tolterodine Drugs 0.000 description 4
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 description 3
- 229960002677 darifenacin Drugs 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229960005042 mequitazine Drugs 0.000 description 3
- 239000003149 muscarinic antagonist Substances 0.000 description 3
- 208000026451 salivation Diseases 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 206010020853 Hypertonic bladder Diseases 0.000 description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 2
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000037020 contractile activity Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000004118 muscle contraction Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 208000020629 overactive bladder Diseases 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 208000015924 Lithiasis Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 208000031709 Skin Manifestations Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 239000000219 Sympatholytic Substances 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000004903 cardiac system Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 230000009989 contractile response Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229940099170 ditropan Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 230000000742 histaminergic effect Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 1
- 229960004633 pirenzepine Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 230000002226 simultaneous effect Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 208000022170 stress incontinence Diseases 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 229940127230 sympathomimetic drug Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0656002 | 2006-12-28 | ||
| FR0656002A FR2910814B1 (fr) | 2006-12-28 | 2006-12-28 | Utilisation du 10-°(r3)-1-azabicyclo°2.2.2!oct-3-ylmethyl!-10h- phenothiazine pour la preparation d'un medicament exercant une inhibition selective des recepteurs muscariniques m1,2,3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2009128326A RU2009128326A (ru) | 2011-02-10 |
| RU2449794C2 true RU2449794C2 (ru) | 2012-05-10 |
Family
ID=37951872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009128326/15A RU2449794C2 (ru) | 2006-12-28 | 2007-12-26 | Применение 10-[(3r)-1-азабицикло[2.2.2]окт-3-илметил]-10н-фенотиазина для изготовления лекарства, селективно ингибирующего мускариновые рецепторы м1, м2 и м3 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8143245B2 (enExample) |
| EP (1) | EP2124956A1 (enExample) |
| JP (1) | JP5564263B2 (enExample) |
| KR (1) | KR101465277B1 (enExample) |
| CN (1) | CN101573120B (enExample) |
| AR (1) | AR064714A1 (enExample) |
| AU (1) | AU2007341274B2 (enExample) |
| BR (1) | BRPI0720591A2 (enExample) |
| CA (1) | CA2674162A1 (enExample) |
| FR (2) | FR2910814B1 (enExample) |
| IL (1) | IL199557A (enExample) |
| MA (1) | MA31026B1 (enExample) |
| MX (1) | MX2009006950A (enExample) |
| NO (1) | NO20092654L (enExample) |
| NZ (1) | NZ577915A (enExample) |
| RU (1) | RU2449794C2 (enExample) |
| TN (1) | TN2009000257A1 (enExample) |
| TW (1) | TWI423806B (enExample) |
| UA (1) | UA98131C2 (enExample) |
| WO (1) | WO2008080924A1 (enExample) |
| ZA (1) | ZA200904304B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015133989A (ja) * | 2015-04-28 | 2015-07-27 | 重泉 達志 | 健康食品 |
| KR101969263B1 (ko) | 2018-07-16 | 2019-04-15 | 이상호 | 산소 챔버용 산소 공급 장치 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603132A (en) * | 1984-03-16 | 1986-07-29 | Laboratori Guidotti S.P.A. | Phenothiazine compounds with anti-bronchospastic activity and pharmaceutical compositions containing them |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1251161B (it) * | 1991-08-07 | 1995-05-04 | Derivati ammonio quaternari di (-) e (+)-3-(10 h-fenotiazin-10-ilmetil)-l-azabiciclo (2.2.2.)ottano e composizioni farmaceutiche che li contengono | |
| AU6686700A (en) | 1999-08-23 | 2001-03-19 | H. Lundbeck A/S | Treatment of urinary incontinence |
| AU2002366800B2 (en) * | 2001-12-20 | 2006-08-03 | Femmepharma Holding Company, Inc. | Vaginal delivery of drugs |
-
2006
- 2006-12-28 FR FR0656002A patent/FR2910814B1/fr not_active Expired - Fee Related
-
2007
- 2007-12-13 TW TW096147644A patent/TWI423806B/zh not_active IP Right Cessation
- 2007-12-26 NZ NZ577915A patent/NZ577915A/en not_active IP Right Cessation
- 2007-12-26 US US12/521,067 patent/US8143245B2/en not_active Expired - Fee Related
- 2007-12-26 RU RU2009128326/15A patent/RU2449794C2/ru not_active IP Right Cessation
- 2007-12-26 JP JP2009543465A patent/JP5564263B2/ja not_active Expired - Fee Related
- 2007-12-26 KR KR1020097013047A patent/KR101465277B1/ko not_active Expired - Fee Related
- 2007-12-26 WO PCT/EP2007/064553 patent/WO2008080924A1/fr not_active Ceased
- 2007-12-26 BR BRPI0720591-0A patent/BRPI0720591A2/pt not_active IP Right Cessation
- 2007-12-26 MX MX2009006950A patent/MX2009006950A/es active IP Right Grant
- 2007-12-26 AU AU2007341274A patent/AU2007341274B2/en not_active Ceased
- 2007-12-26 CN CN2007800467680A patent/CN101573120B/zh not_active Expired - Fee Related
- 2007-12-26 EP EP07858150A patent/EP2124956A1/fr not_active Withdrawn
- 2007-12-26 CA CA002674162A patent/CA2674162A1/fr not_active Abandoned
- 2007-12-26 UA UAA200907928A patent/UA98131C2/ru unknown
- 2007-12-28 AR ARP070105989A patent/AR064714A1/es unknown
-
2009
- 2009-01-01 ZA ZA200904304A patent/ZA200904304B/xx unknown
- 2009-06-23 TN TNP2009000257A patent/TN2009000257A1/fr unknown
- 2009-06-25 IL IL199557A patent/IL199557A/en not_active IP Right Cessation
- 2009-06-26 MA MA32046A patent/MA31026B1/fr unknown
- 2009-07-13 NO NO20092654A patent/NO20092654L/no not_active Application Discontinuation
-
2011
- 2011-03-17 FR FR1152199A patent/FR2953721A1/fr active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603132A (en) * | 1984-03-16 | 1986-07-29 | Laboratori Guidotti S.P.A. | Phenothiazine compounds with anti-bronchospastic activity and pharmaceutical compositions containing them |
Non-Patent Citations (3)
| Title |
|---|
| реферат [он-лайн] [найдено 2011-07-06] (Найдено из базы данных Esp@cenet). Kubo N et al. Antimuscarinic effects of antihistamines: quantitative evaluation by receptor-binding assay. Jpn J Pharmacol. 1987 Mar; 43 (3):277-82. [он-лайн] [найдено 2011-07-06] (Найдено из базы данных PubMed PMID: 2884340). Stanton Т et al. Antagonism of the five cloned human muscarinic cholinergic recaptors expressed in CHO-K1 cells by antidepressants and antihistaminics. Biochem Pharmacol. 1993 Jun 9:45(11):2352-4. Реферат [он-лайн] [найдено 2011-07-06] (Найдено из базы данных PubMed PMID: 8100134). * |
| ЭНЦИКЛОПЕДИЧЕСКИЙ СЛОВАРЬ МЕДИЦИНСКИХ ТЕРМИНОВ. - М.: Медицина, 2001, с.698. * |
| ЭНЦИКЛОПЕДИЯ ЛЕКАРСТВ. - М.: ООО «РЛС-2005», 2004, с.538, 728-729. Shi L. et al. [Effects of dexamethasone on the expression of muscarinic receptor mRNA in asthmatic guinea pig airway smooth muscle and eosinophil infiltration in bronchoalveolar lavage fluid]. Di Yi Jun Yi Da Xue Xue Bao. 2005 Aug; 25(8):986-90. Реферат [он-лайн] [найдено 2011-07-06] (Найдено из базы данных PubMed PMID: 16109556). Sweeney М et al. Role of capacitative Ca2+ entry in bronchial contraction and remodeling. J Appl Physiol. 2002 Apr; 92(4): 1594-602. [он-лайн] [найдено 2011-07-06] (Найдено из базы данных PubMed PMID: 11896026). БАЗА ДАННЫХ REGISTRY RN 147780-50-5 Entered STN: 27 May 1993 [он-лайн] [найдено 2011-07-06] (Найдено из базы данных STN). * |
Also Published As
| Publication number | Publication date |
|---|---|
| US8143245B2 (en) | 2012-03-27 |
| JP2010514730A (ja) | 2010-05-06 |
| KR101465277B1 (ko) | 2014-11-27 |
| MX2009006950A (es) | 2009-07-14 |
| AR064714A1 (es) | 2009-04-22 |
| AU2007341274A1 (en) | 2008-07-10 |
| RU2009128326A (ru) | 2011-02-10 |
| JP5564263B2 (ja) | 2014-07-30 |
| FR2953721A1 (fr) | 2011-06-17 |
| AU2007341274B2 (en) | 2012-09-20 |
| HK1133207A1 (en) | 2010-03-19 |
| BRPI0720591A2 (pt) | 2014-02-25 |
| NZ577915A (en) | 2011-12-22 |
| CN101573120A (zh) | 2009-11-04 |
| TWI423806B (zh) | 2014-01-21 |
| UA98131C2 (ru) | 2012-04-25 |
| KR20090103887A (ko) | 2009-10-01 |
| TN2009000257A1 (fr) | 2010-10-18 |
| WO2008080924A1 (fr) | 2008-07-10 |
| NO20092654L (no) | 2009-09-28 |
| EP2124956A1 (fr) | 2009-12-02 |
| FR2910814B1 (fr) | 2011-06-17 |
| CN101573120B (zh) | 2011-11-23 |
| TW200833331A (en) | 2008-08-16 |
| FR2910814A1 (fr) | 2008-07-04 |
| ZA200904304B (en) | 2010-06-30 |
| CA2674162A1 (fr) | 2008-07-10 |
| US20100063276A1 (en) | 2010-03-11 |
| MA31026B1 (fr) | 2009-12-01 |
| IL199557A (en) | 2014-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2484821C2 (ru) | Новые способы | |
| US6559186B1 (en) | Compositions and methods of treatment of sympathetically maintained pain | |
| WO1992014453A1 (en) | Compositions and methods of treatment of sympathetically maintained pain | |
| BRPI0615432A2 (pt) | composição farmacêutica, e, uso de compostos | |
| RU2290929C2 (ru) | Фармацевтическая композиция для лечения интерстициального цистита | |
| JP2007536269A (ja) | ゴニオトキシンを用いた創傷の治療方法 | |
| KR20000075572A (ko) | 뇨 실금, 동요병 및 어지러움을 치료하는 약물을 제조하는데있어서 데스카르보에톡시로라타딘을 이용하는 방법 | |
| EP0918518A4 (en) | TREATMENT OF MIND AND MOOD DISEASES WITH GLUTAMATERGIC MODULATORS. | |
| KR20100040294A (ko) | 전립선 비대에 수반되는 하부 요로 증상의 개선용 의약 조성물 | |
| ES2322954T3 (es) | Agonistas del adrenoceptor alfa 2b o 2b/2c para el tratamiento de la enfermedad de alzheimer y la enfermedad de parkinson. | |
| US8143245B2 (en) | Use of 10-[(3R)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine for the preparation of a drug having a selective inhibition of muscarinic M1, M2, and M3 receptors | |
| AU2014365665B2 (en) | Use of PAR-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions | |
| KR20220054593A (ko) | 병용 치료를 위한 화합물 | |
| US20040248932A1 (en) | Use of aryl- and heteroaryl-substituted tetrahydroisoquinolines in the treatment of chronic and neuropathic pain, migraine headaches, and urge, stress and mixed urinary incontinence | |
| JP2010538974A (ja) | ベンズアミド誘導体、その調製および医薬におけるその使用 | |
| Blaze et al. | Veterinary Anesthesia Drug Quick Reference-E-Book: Veterinary Anesthesia Drug Quick Reference-E-Book | |
| HK1133207B (en) | Use of 10-[(3r)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10h-phenothiazine for the preparation of a drug having a selective inhibition of muscarinic m1, m2 and m3 receptors | |
| KR20080058465A (ko) | 복압요실금 및 혼합 요실금의 치료 | |
| Wein et al. | Pharmacologic management of urinary incontinence | |
| Aronson | New antihistamines | |
| MXPA99007802A (es) | Uso de descarboetociloratadina para la preparacion de un farmaco para el tratamiento de la incontinencia urinaria, malestar causado por el movimiento y vertigo | |
| HK1221913B (en) | Use of par-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20151227 |